Indication

Eosinophils

1 clinical trial

1 product

Clinical trial

An Open-Label Extension Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma

Status: Terminated, Estimated PCD: 2018-02-22

Product